Three different hTERT-immortalized human primary renal proximal tubule epithelial cells (RPTEC) were modified and tested for functionality and stable expression of the OAT1, OCT2, and OAT3 proteins.

[21] Many other cells can be seen in urine and are of variable clinical significance. Renal tubule epithelial cells can be oval to columnar in shape, depending on the segment of the tubule they ...

Developing advanced drug screening tools is crucial for the advancement of personalized medicine and the creation of more ...

Developing advanced drug screening tools is crucial for the advancement of personalized medicine and the creation of more ...

Researchers from USC and Caltech used advanced technology to map changes in cells, molecules, and structures after acute ...

The accumulation of SIRT4 in the nuclei of kidney cells drives kidney fibrosis, so blocking the movement of this protein could be a potential therapeutic strategy against fibrosis.

(d) This ESC-RCC harbors a TSC2 (c.292del p.R98Gfs*8) mutation. Advances in immunohistochemical and molecular technologies have led to the identification of various new renal cell carcinoma (RCC) ...

HGF also demonstrates anti-apoptotic effects on several different cell types, including cardiomyocytes, renal tubular cells ... and other cells (such as endothelial and epithelial cells) release ...

NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics tar ...

Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Phase II for Renal Cell Carcinoma.

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Phase II for Epithelial Ovarian Cancer.